vs
Side-by-side financial comparison of Community West Bancshares (CWBC) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $38.3M, roughly 1.8× Community West Bancshares). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 11.6%). Community West Bancshares produced more free cash flow last quarter ($43.6M vs $-84.7M).
Community West BancsharesCWBCEarnings & Financial Report
Community West Bancshares is a registered bank holding company headquartered in California. It wholly owns Community West Bank under the Bank Holding Company Act.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
CWBC vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $70.6M |
| Net Profit | — | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 40.0% | -56.7% |
| Net Margin | — | -49.0% |
| Revenue YoY | 11.6% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | — | ||
| Q3 25 | $37.9M | $70.6M | ||
| Q2 25 | $35.7M | — | ||
| Q1 25 | $34.8M | — | ||
| Q4 24 | $34.3M | — | ||
| Q3 24 | $31.3M | — | ||
| Q2 24 | $30.5M | — | ||
| Q1 24 | $20.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | $10.9M | $-34.6M | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $8.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $-6.3M | — | ||
| Q1 24 | $3.7M | — |
| Q4 25 | 40.0% | — | ||
| Q3 25 | 39.8% | -56.7% | ||
| Q2 25 | 30.2% | — | ||
| Q1 25 | 32.7% | — | ||
| Q4 24 | 31.0% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | -25.9% | — | ||
| Q1 24 | 23.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 28.7% | -49.0% | ||
| Q2 25 | 22.0% | — | ||
| Q1 25 | 23.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | -20.7% | — | ||
| Q1 24 | 17.8% | — |
| Q4 25 | $0.58 | — | ||
| Q3 25 | $0.57 | — | ||
| Q2 25 | $0.41 | — | ||
| Q1 25 | $0.44 | — | ||
| Q4 24 | $0.29 | — | ||
| Q3 24 | $0.18 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $119.0M | $490.9M |
| Total DebtLower is stronger | $69.5M | — |
| Stockholders' EquityBook value | $409.6M | $503.0M |
| Total Assets | $3.7B | $577.1M |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.0M | — | ||
| Q3 25 | $121.6M | $490.9M | ||
| Q2 25 | $134.4M | — | ||
| Q1 25 | $148.4M | — | ||
| Q4 24 | $120.4M | — | ||
| Q3 24 | $149.0M | — | ||
| Q2 24 | $109.7M | — | ||
| Q1 24 | $61.0M | — |
| Q4 25 | $69.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $69.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $409.6M | — | ||
| Q3 25 | $397.6M | $503.0M | ||
| Q2 25 | $380.0M | — | ||
| Q1 25 | $372.2M | — | ||
| Q4 24 | $362.7M | — | ||
| Q3 24 | $363.5M | — | ||
| Q2 24 | $350.2M | — | ||
| Q1 24 | $211.7M | — |
| Q4 25 | $3.7B | — | ||
| Q3 25 | $3.6B | $577.1M | ||
| Q2 25 | $3.6B | — | ||
| Q1 25 | $3.6B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.5B | — | ||
| Q1 24 | $2.4B | — |
| Q4 25 | 0.17× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.1M | $-84.6M |
| Free Cash FlowOCF − Capex | $43.6M | $-84.7M |
| FCF MarginFCF / Revenue | 113.9% | -120.1% |
| Capex IntensityCapex / Revenue | 6.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.1M | — | ||
| Q3 25 | $13.2M | $-84.6M | ||
| Q2 25 | $11.5M | — | ||
| Q1 25 | $11.1M | — | ||
| Q4 24 | $22.2M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $4.0M | — |
| Q4 25 | $43.6M | — | ||
| Q3 25 | $12.8M | $-84.7M | ||
| Q2 25 | $10.6M | — | ||
| Q1 25 | $10.8M | — | ||
| Q4 24 | $17.2M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | $4.8M | — | ||
| Q1 24 | $3.6M | — |
| Q4 25 | 113.9% | — | ||
| Q3 25 | 33.7% | -120.1% | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 30.9% | — | ||
| Q4 24 | 50.0% | — | ||
| Q3 24 | 16.7% | — | ||
| Q2 24 | 15.7% | — | ||
| Q1 24 | 17.3% | — |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 1.1% | 0.2% | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
